Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues

This article was originally published in The Tan Sheet

Executive Summary

Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups

You may also be interested in...



Kratom Action Presents Regulatory Puzzle For FDA

The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.

Kratom Action Presents Regulatory Puzzle For FDA

The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.

FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door

USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.

Related Content

Topics

UsernamePublicRestriction

Register

PS100534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel